Amino Acid and Lipid Metabolism in Cancer: Mechanisms and Therapeutic Opportunities

Abstract

Metabolic reprogramming is a defining feature of cancer and a major contributor to immune escape. Beyond the well-defined glycolysis, dysregulated amino acid and lipid metabolism also regulate tumor growth, stress adaptation, and therapeutic resistance. Amino acids such as glutamine, arginine, tryptophan, methionine, serine, and cysteine shape biosynthesis, redox balance, one-carbon metabolism, epigenetic control, and nutrient competition in the tumor microenvironment. Lipid uptake, de novo lipogenesis, fatty acid oxidation, cholesterol remodeling, COX-PGE2 signaling, sphingolipid metabolism, and ferroptosis further influence antigen presentation, immune cell fitness, and checkpoint regulation. However, most studies still consider these metabolic axes separately, leaving the coordinated amino acid–lipid crosstalk across tumor and immune compartments insufficiently defined. This review synthesizes recent advances in amino acid metabolism, including the glutamine axis, arginine-polyamine biology, the tryptophan–kynurenine–AHR pathway, and methionine-dependent methylation programs. It then discusses lipid metabolic programs that regulate dendritic cell cross-presentation, suppressive myeloid polarization, CD8⁺ T cell exhaustion, PD-L1 palmitoylation, MHC-I stability, and lipid-peroxidation-linked ferroptosis. We further integrate nutrient competition, immunometabolic checkpoints, and dual metabolic targeting strategies with immune checkpoint blockade. This review provides a unified framework for identifying metabolic vulnerabilities, designing rational combination therapies and refining precision cancer immunotherapy.

Keywords

amino acid metabolism / cancer immunotherapy / immune evasion / lipid metabolism / metabolic reprogramming

References

[1] A. Passaro, M. Al Bakir, E. G. Hamilton, et al., “Cancer Biomarkers: Emerging Trends and Clinical Implications for Personalized Treatment,” Cell 187 (2024): 1617–1635.

[2] P. S. Ward and C. B. Thompson, “Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate,” Cancer Cell 21 (2012): 297–308.

[3] M. G. Vander Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,” Science 324 (2009): 1029–1033.

[4] N. G. Hammond, R. B. Cameron, and B. Faubert, “Beyond Glucose and Warburg: Finding the Sweet Spot in Cancer Metabolism Models,” npj Metabolic Health and Disease 2 (2024): 11.

[5] Y. Liu, Y. Zhao, H. Song, et al., “Metabolic Reprogramming in Tumor Immune Microenvironment: Impact on Immune Cell Function and Therapeutic Implications,” Cancer Letters 597 (2024): 217076.

[6] T. Hu, C. H. Liu, M. Lei, et al., “Metabolic Regulation of the Immune System in Health and Diseases: Mechanisms and Interventions,” Signal Transduction and Targeted Therapy 9 (2024): 268.

[7] G. S. Ducker and J. D. Rabinowitz, “One-Carbon Metabolism in Health and Disease,” Cell Metabolism 25 (2017): 27–42.

[8] X. Li and H.-S. Zhang, “Amino Acid Metabolism, Redox Balance and Epigenetic Regulation in Cancer,” The FEBS Journal 291 (2024): 412–429.

[9] S. Solanki, K. Sanchez, V. Ponnusamy, et al., “Dysregulated Amino Acid Sensing Drives Colorectal Cancer Growth and Metabolic Reprogramming Leading to Chemoresistance,” Gastroenterology 164 (2023): 376–391.e313.

[10] L. Yang, Z. Chu, M. Liu, et al., “Amino Acid Metabolism in Immune Cells: Essential Regulators of the Effector Functions, and Promising Opportunities to Enhance Cancer Immunotherapy,” Journal of Hematology & Oncology 16 (2023): 59.

[11] M. Morotti, C. E. Zois, R. El-Ansari, et al., “Increased Expression of Glutamine Transporter SNAT2/SLC38A2 Promotes Glutamine Dependence and Oxidative Stress Resistance, and Is Associated With Worse Prognosis in Triple-Negative Breast Cancer,” British Journal of Cancer 124 (2021): 494–505.

[12] G. Shu, M. Chen, W. Liao, et al., “PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma,” Cancer Research 84 (2024): 1659–1679.

[13] J. Wang, Y. He, F. Hu, et al., “Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment,” International Journal of Molecular Sciences 25 (2024): 12223.

[14] S. Sun, M. Deng, J. Wen, et al., “Aspartate Beta-Hydroxylase Domain Containing 1 as a Prognostic Marker Associated With Immune Infiltration in Skin Cutaneous Melanoma,” BMC Cancer 23 (2023): 292.

[15] X. Hu, Z. Ma, B. Xu, et al., “Glutamine Metabolic Microenvironment Drives M2 Macrophage Polarization to Mediate Trastuzumab Resistance in HER2-Positive Gastric Cancer,” Cancer Communications 43 (2023): 909–937.

[16] M. T. Snaebjornsson, S. Janaki-Raman, and A. Schulze, “Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer,” Cell Metabolism 31 (2020): 62–76.

[17] L. A. Broadfield, A. A. Pane, A. Talebi, J. V. Swinnen, and S.-M. Fendt, “Lipid Metabolism in Cancer: New Perspectives and Emerging Mechanisms,” Developmental Cell 56 (2021): 1363–1393.

[18] S. Xu, O. Chaudhary, P. Rodríguez-Morales, et al., “Uptake of Oxidized Lipids by the Scavenger Receptor CD36 Promotes Lipid Peroxidation and Dysfunction in CD8+ T Cells in Tumors,” Immunity 54 (2021): 1561–1577.e1567.

[19] Y. Tang, Z. Chen, Q. Zuo, and Y. Kang, “Regulation of CD8+ T Cells by Lipid Metabolism in Cancer Progression,” Cellular & Molecular Immunology 21 (2024): 1215–1230.

[20] G. Marelli, N. Morina, F. Portale, et al., “Lipid-Loaded Macrophages as New Therapeutic Target in Cancer,” Journal for Immunotherapy of Cancer 10 (2022): e004584.

[21] B. Kelly and E. L. Pearce, “Amino Assets: How Amino Acids Support Immunity,” Cell Metabolism 32 (2020): 154–175.

[22] N. S. Chandel, “Amino Acid Metabolism,” Cold Spring Harbor Perspectives in Biology 13 (2021): a040584.

[23] Z. Wei, X. Liu, C. Cheng, W. Yu, and P. Yi, “Metabolism of Amino Acids in Cancer,” Frontiers in Cell and Developmental Biology 8 (2021): 2020.

[24] M. Scalise and C. Indiveri, “Amino Acids Transport and Metabolism 2.0,” International Journal of Molecular Sciences 21 (2020): 1212.

[25] G. Gauthier-Coles, J. Vennitti, Z. Zhang, et al., “Quantitative Modelling of Amino Acid Transport and Homeostasis in Mammalian Cells,” Nature Communications 12 (2021): 5282.

[26] D. R. Wise, R. J. DeBerardinis, A. Mancuso, et al., “Myc Regulates a Transcriptional Program That Stimulates Mitochondrial Glutaminolysis and Leads to Glutamine Addiction,” PNAS 105 (2008): 18782–18787.

[27] J. Chen, R. Wang, Z. Liu, et al., “Unbalanced Glutamine Partitioning Between CD8T Cells and Cancer Cells Accompanied by Immune Cell Dysfunction in Hepatocellular Carcinoma,” Cells 11 (2022): 3924.

[28] E. Dn, N. Vm, R. Al, et al., “Selective Glutamine Metabolism Inhibition in Tumor Cells Improves Antitumor T Lymphocyte Activity in Triple-Negative Breast Cancer,” The Journal of Clinical Investigation 131 (2021): e140100.

[29] R. Keshet, P. Szlosarek, A. Carracedo, and A. Erez, “Rewiring Urea Cycle Metabolism in Cancer to Support Anabolism,” Nature Reviews Cancer 18 (2018): 634–645.

[30] S. M. Steggerda, M. K. Bennett, J. Chen, et al., “Inhibition of Arginase by CB-1158 Blocks Myeloid Cell-Mediated Immune Suppression in the Tumor Microenvironment,” Journal for ImmunoTherapy of Cancer 5 (2017): 101.

[31] R. E. Menjivar, Z. C. Nwosu, W. Du, et al., “Arginase 1 Is a Key Driver of Immune Suppression in Pancreatic Cancer,” Elife 12 (2023): e80721.

[32] M. Platten, E. A. A. Nollen, U. F. Röhrig, F. Fallarino, and C. A. Opitz, “Tryptophan Metabolism as a Common Therapeutic Target in Cancer, Neurodegeneration and Beyond,” Nature Reviews Drug Discovery 18 (2019): 379–401.

[33] L. F. Campesato, S. Budhu, J. Tchaicha, et al., “Blockade of the AHR Restricts a Treg-Macrophage Suppressive Axis Induced by L-Kynurenine,” Nature Communications 11 (2020): 4011.

[34] J. Yan, D. Chen, Z. Ye, et al., “Molecular Mechanisms and Therapeutic Significance of Tryptophan Metabolism and Signaling in Cancer,” Molecular Cancer 23 (2024): 241.

[35] K. Odunsi, F. Qian, A. A. Lugade, et al., “Metabolic Adaptation of Ovarian Tumors in Patients Treated With an IDO1 Inhibitor Constrains Antitumor Immune Responses,” Science Translational Medicine 14 (2022): eabg8402.

[36] O. D. Maddocks, C. F. Labuschagne, P. D. Adams, and K. H. Vousden, “Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation Through De Novo ATP Synthesis in Cancer Cells,” Molecular Cell 61 (2016): 210–221.

[37] B. Petrova, A. G. Maynard, P. Wang, and N. Kanarek, “Regulatory Mechanisms of One-Carbon Metabolism Enzymes,” Journal of Biological Chemistry 299 (2023): 105457.

[38] E. Białopiotrowicz, M. Noyszewska-Kania, N. Kachamakova-Trojanowska, et al., “Serine Biosynthesis Pathway Supports MYC-miR-494-EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells,” Cancers (Basel) 12 (2020): 580.

[39] T. Li, Y.-T. Tan, Y.-X. Chen, et al., “Methionine Deficiency Facilitates Antitumour Immunity by Altering m6A Methylation of Immune Checkpoint Transcripts,” Gut 72 (2023): 501–511.

[40] Z. Wang, L. Y. Yip, J. H. J. Lee, et al., “Methionine Is a Metabolic Dependency of Tumor-Initiating Cells,” Nature Medicine 25 (2019): 825–837.

[41] P. Kalev, M. L. Hyer, S. Gross, et al., “MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage,” Cancer Cell 39 (2021): 209–224.e211.

[42] D. Mossmann, C. Müller, S. Park, et al., “Arginine Reprograms Metabolism in Liver Cancer via RBM39,” Cell 186 (2023): 5068–5083.e5023.

[43] P.-S. Liu, Y.-T. Chen, X. Li, et al., “CD40 Signal Rewires Fatty Acid and Glutamine Metabolism for Stimulating Macrophage Anti-Tumorigenic Functions,” Nature Immunology 24 (2023): 452–462.

[44] L. Colyn, G. Alvarez-Sola, M. U. Latasa, et al., “New Molecular Mechanisms in Cholangiocarcinoma: Signals Triggering Interleukin-6 Production in Tumor Cells and KRAS Co-Opted Epigenetic Mediators Driving Metabolic Reprogramming,” Journal of Experimental & Clinical Cancer Research 41 (2022): 183.

[45] J. Edwards-Hicks, H. Su, M. Mangolini, et al., “MYC Sensitises Cells to Apoptosis by Driving Energetic Demand,” Nature Communications 13 (2022): 4674.

[46] A. Jaggupilli, S. Ly, K. Nguyen, et al., “Metabolic Stress Induces GD2+ Cancer Stem Cell-Like Phenotype in Triple-Negative Breast Cancer,” British Journal of Cancer 126 (2022): 615–627.

[47] A. Mukha, U. Kahya, A. Linge, et al., “GLS-Driven Glutamine Catabolism Contributes to Prostate Cancer Radiosensitivity by Regulating the Redox State, Stemness and ATG5-Mediated Autophagy,” Theranostics 11 (2021): 7844–7868.

[48] H. Kurniawan, D. G. Franchina, L. Guerra, et al., “Glutathione Restricts Serine Metabolism to Preserve Regulatory T Cell Function,” Cell Metabolism 31 (2020): 920–936.e927.

[49] P. V. Raninga, Y. He, K. K. Datta, et al., “Combined Thioredoxin Reductase and Glutaminase Inhibition Exerts Synergistic Anti-Tumor Activity in MYC-High High-Grade Serous Ovarian Carcinoma,” Molecular Therapy 31 (2023): 729–743.

[50] Q. Zhou, W. Lin, C. Wang, et al., “Neddylation Inhibition Induces Glutamine Uptake and Metabolism by Targeting CRL3SPOP E3 Ligase in Cancer Cells,” Nature Communications 13 (2022): 3034.

[51] X. Liu, H. Qin, Z. Li, et al., “Inspiratory Hyperoxia Suppresses Lung Cancer Metastasis Through a MYC/SLC1A5-Dependent Metabolic Pathway,” European Respiratory Journal 60 (2022): 2200062.

[52] R. E. Ansari, M. L. Craze, M. Althobiti, et al., “Enhanced Glutamine Uptake Influences Composition of Immune Cell Infiltrates in Breast Cancer,” British Journal of Cancer 122 (2020): 94–101.

[53] S. Varghese, S. Pramanik, L. J. Williams, et al., “The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies,” Molecular Cancer Therapeutics 20 (2021): 500–511.

[54] Y. Zhao, X. Feng, Y. Chen, et al., “5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 Against PIK3CA-Mutant Colorectal Cancers,” Cancer Research 80 (2020): 4815–4827.

[55] A. Ikeda, S. Nagayama, M. Sumazaki, et al., “Colorectal Cancer-Derived CAT1-Positive Extracellular Vesicles Alter Nitric Oxide Metabolism in Endothelial Cells and Promote Angiogenesis,” Molecular Cancer Research 19 (2021): 834–846.

[56] G. Lu, R. Du, B. Feng, et al., “A Novel Gene Signature Associated With Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients With HCC,” Journal of Inflammation Research 15 (2022): 6729–6743.

[57] C. Shen and Y. Wang, “Ferroptosis Biomarkers for Predicting Prognosis and Immunotherapy Efficacy in Adrenocortical Carcinoma,” Archives of Medical Research 54 (2023): 45–55.

[58] K. Okita, Y. Hara, H. Okura, et al., “Antitumor Effects of Novel mAbs Against Cationic Amino Acid Transporter 1 (CAT1) on Human CRC With Amplified CAT1 Gene,” Cancer Science 112 (2021): 563–574.

[59] R. Missiaen, N. M. Anderson, L. C. Kim, et al., “GCN2 inhibition Sensitizes Arginine-Deprived Hepatocellular Carcinoma Cells to Senolytic Treatment,” Cell Metabolism 34 (2022): 1151–1167.e1157.

[60] M. T. Agulló-Ortuño, E. Mancebo, M. Grau, et al., “Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models,” International Journal of Molecular Sciences 24 (2023): 13005.

[61] C. Kober, J. Roewe, N. Schmees, et al., “Targeting the Aryl Hydrocarbon Receptor (AhR) With BAY 2416964: A Selective Small Molecule Inhibitor for Cancer Immunotherapy,” Journal for Immunotherapy of Cancer 11 (2023): e007495.

[62] C. Uyttenhove, L. Pilotte, I. Théate, et al., “Evidence for a Tumoral Immune Resistance Mechanism Based on Tryptophan Degradation by Indoleamine 2,3-Dioxygenase,” Nature Medicine 9 (2003): 1269–1274.

[63] C. A. Opitz, U. M. Litzenburger, F. Sahm, et al., “An Endogenous Tumour-Promoting Ligand of the Human Aryl Hydrocarbon Receptor,” Nature 478 (2011): 197–203.

[64] A. Lewis-Ballester, K. N. Pham, D. Batabyal, et al., “Structural Insights Into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1,” Nature Communications 8 (2017): 1693.

[65] A. Naing, J. D. Powderly, J. J. Nemunaitis, et al., “Exploring the Safety, Effect on the Tumor Microenvironment, and Efficacy of Itacitinib in Combination With Epacadostat or Parsaclisib in Advanced Solid Tumors: A Phase I Study,” Journal for Immunotherapy of Cancer 10 (2022): e004223.

[66] T. C. Mitchell, O. Hamid, D. C. Smith, et al., “Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037),” Journal of Clinical Oncology 36 (2018): 3223–3230.

[67] E. Pranzini, E. Pardella, L. Muccillo, et al., “SHMT2-Mediated Mitochondrial Serine Metabolism Drives 5-FU Resistance by Fueling Nucleotide Biosynthesis,” Cell Reports 40 (2022): 111233.

[68] K. Hu, K. Li, J. Lv, et al., “Suppression of the SLC7A11/Glutathione Axis Causes Synthetic Lethality in KRAS-Mutant Lung Adenocarcinoma,” The Journal of Clinical Investigation 130 (2020): 1752–1766.

[69] W. Xie, I. Kagiampakis, L. Pan, et al., “DNA Methylation Patterns Separate Senescence From Transformation Potential and Indicate Cancer Risk,” Cancer Cell 33 (2018): 309–321.e305.

[70] W. Fan, D. Cao, B. Yang, et al., “Hepatic Prohibitin 1 and Methionine Adenosyltransferase α1 Defend Against Primary and Secondary Liver Cancer Metastasis,” Journal of Hepatology 80 (2024): 443–453.

[71] G. T. Bedard, N. Gilaj, K. Peregrina, et al., “Combined Inhibition of MTAP and MAT2a Mimics Synthetic Lethality in Tumor Models via PRMT5 Inhibition,” Journal of Biological Chemistry 300 (2024): 105492.

[72] P. Koppula, L. Zhuang, and B. Gan, “Cystine Transporter SLC7A11/xCT in Cancer: Ferroptosis, Nutrient Dependency, and Cancer Therapy,” Protein & Cell 12 (2021): 599–620.

[73] C. Han, M. Ge, P. Xing, et al., “Cystine Deprivation Triggers CD36-Mediated Ferroptosis and Dysfunction of Tumor Infiltrating CD8+ T Cells,” Cell Death & Disease 15 (2024): 145.

[74] J. Wu, G. Li, L. Li, et al., “Asparagine Enhances LCK Signalling to Potentiate CD8+ T-Cell Activation and Anti-Tumour Responses,” Nature Cell Biology 23 (2021): 75–86.

[75] J. N. R. Gnanaprakasam, B. Kushwaha, L. Liu, et al., “Asparagine Restriction Enhances CD8+ T Cell Metabolic Fitness and Antitumoral Functionality Through an NRF2-Dependent Stress Response,” Nature Metabolism 5 (2023): 1423–1439.

[76] L. Hinze, R. Labrosse, J. Degar, et al., “Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy,” Cancer Discovery 10 (2020): 1690–1705.

[77] S. Mazloum-Ravasan, E. Madadi, A. Mohammadi, et al., “Yarrowia Lipolytica L-Asparaginase Inhibits the Growth and Migration of Lung (A549) and Breast (MCF7) Cancer Cells,” International Journal of Biological Macromolecules 170 (2021): 406–414.

[78] Y. Zhang, H. Hu, W. Liu, et al., “Amino Acids and RagD Potentiate mTORC1 Activation in CD8+ T Cells to Confer Antitumor Immunity,” Journal for Immunotherapy of Cancer 9 (2021): e002137.

[79] N. E. Cook, M. R. McGovern, T. Zaman, P. M. Lundin, and R. A. Vaughan, “Effect of mTORC Agonism via MHY1485 With and Without Rapamycin on C2C12 Myotube Metabolism,” International Journal of Molecular Sciences 25 (2024): 6819.

[80] B. H. Choi, S. Hyun, and S. H. Koo, “The Role of BCAA Metabolism in Metabolic Health and Disease,” Experimental & Molecular Medicine 56 (2024): 1552–1559.

[81] T. Y. Chia, A. Zolp, and J. Miska, “Polyamine Immunometabolism: Central Regulators of Inflammation, Cancer and Autoimmunity,” Cells 11 (2022): 896.

[82] M. Li, S. Wu, C. Zhuang, et al., “Metabolomic Analysis of Circulating Tumor Cells Derived Liver Metastasis of Colorectal Cancer,” Heliyon 9 (2023): e12515.

[83] J. Guillard and S. Schwörer, “Metabolic Control of Collagen Synthesis,” Matrix Biology 133 (2024): 43–56.

[84] Y. Ji, H. Zhang, F. L. Gong, et al., “The Expression and Functional Role of Proline-Rich 15 in Non-Small Cell Lung Cancer,” Cell Death & Disease 16 (2025): 83.

[85] A. L. Mellor and D. H. Munn, “IDO Expression by Dendritic Cells: Tolerance and Tryptophan Catabolism,” Nature Reviews Immunology 4 (2004): 762–774.

[86] D. L. Herber, W. Cao, Y. Nefedova, et al., “Lipid Accumulation and Dendritic Cell Dysfunction in Cancer,” Nature Medicine 16 (2010): 880–886.

[87] R. Ramakrishnan, V. A. Tyurin, F. Veglia, et al., “Oxidized Lipids Block Antigen Cross-Presentation by Dendritic Cells in Cancer,” Journal of Immunology 192 (2014): 2920–2931.

[88] F. Veglia, V. A. Tyurin, D. Mohammadyani, et al., “Lipid Bodies Containing Oxidatively Truncated Lipids Block Antigen Cross-Presentation by Dendritic Cells in Cancer,” Nature Communications 8 (2017): 2122.

[89] X. Yin, W. Zeng, B. Wu, et al., “PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction,” Cell Reports 33 (2020): 108278.

[90] G. Pascual, A. Avgustinova, S. Mejetta, et al., “Targeting Metastasis-Initiating Cells Through the Fatty Acid Receptor CD36,” Nature 541 (2017): 41–45.

[91] X. Ma, L. Xiao, L. Liu, et al., “CD36-Mediated Ferroptosis Dampens Intratumoral CD8⁺ T Cell Effector Function and Impairs Their Antitumor Ability,” Cell Metabolism 33 (2021): 1001–1012.e1005.

[92] X. Ma, E. Bi, Y. Lu, et al., “Cholesterol Induces CD8⁺ T Cell Exhaustion in the Tumor Microenvironment,” Cell Metabolism 30 (2019): 143–156.e145.

[93] W. Yang, Y. Bai, Y. Xiong, et al., “Potentiating the Antitumour Response of CD8⁺ T Cells by Modulating Cholesterol Metabolism,” Nature 531 (2016): 651–655.

[94] F. Röhrig and A. Schulze, “The Multifaceted Roles of Fatty Acid Synthesis in Cancer,” Nature Reviews Cancer 16 (2016): 732–749.

[95] J. Huang, W. Y. Tsang, X. N. Fang, et al., “FASN Inhibition Decreases MHC-I Degradation and Synergizes With PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma,” Cancer Research 84 (2024): 855–871.

[96] L. Berod, C. Friedrich, A. Nandan, et al., “De Novo Fatty Acid Synthesis Controls the Fate Between Regulatory T and T Helper 17 Cells,” Nature Medicine 20 (2014): 1327–1333.

[97] P. Su, Q. Wang, E. Bi, et al., “Enhanced Lipid Accumulation and Metabolism Are Required for the Differentiation and Activation of Tumor-Associated Macrophages,” Cancer Research 80 (2020): 1438–1450.

[98] H. Wu, Y. Han, Y. Rodriguez Sillke, et al., “Lipid Droplet-Dependent Fatty Acid Metabolism Controls the Immune Suppressive Phenotype of Tumor-Associated Macrophages,” EMBO Molecular Medicine 11 (2019): e10698.

[99] Z. Liu, W. Liu, W. Wang, et al., “CPT1A-Mediated Fatty Acid Oxidation Confers Cancer Cell Resistance to Immune-Mediated Cytolytic Killing,” PNAS 120 (2023): e2302878120.

[100] F. Hossain, A. A. Al-Khami, D. Wyczechowska, et al., “Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies,” Cancer Immunology Research 3 (2015): 1236–1247.

[101] F. Veglia, V. A. Tyurin, M. Blasi, et al., “Fatty Acid Transport Protein 2 Reprograms Neutrophils in Cancer,” Nature 569 (2019): 73–78.

[102] E. G. Hunt, K. E. Hurst, B. P. Riesenberg, et al., “Acetyl-CoA Carboxylase Obstructs CD8⁺ T Cell Lipid Utilization in the Tumor Microenvironment,” Cell Metabolism 36 (2024): 969–983.e910.

[103] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht, et al., “Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death,” Cell 149 (2012): 1060–1072.

[104] W. Wang, M. Green, J. E. Choi, et al., “CD8⁺ T Cells Regulate Tumour Ferroptosis During Cancer Immunotherapy,” Nature 569 (2019): 270–274.

[105] S. Doll, B. Proneth, Y. Y. Tyurina, et al., “ACSL4 dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition,” Nature Chemical Biology 13 (2017): 91–98.

[106] A. Reed, T. A. Ichu, N. Milosevich, et al., “LPCAT3 Inhibitors Remodel the Polyunsaturated Phospholipid Content of Human Cells and Protect From Ferroptosis,” ACS Chemical Biology 17 (2022): 1607–1618.

[107] M. Matsushita, S. Freigang, C. Schneider, et al., “T Cell Lipid Peroxidation Induces Ferroptosis and Prevents Immunity to Infection,” Journal of Experimental Medicine 212 (2015): 555–568.

[108] X. Liu, X. Bao, M. Hu, et al., “Inhibition of PCSK9 Potentiates Immune Checkpoint Therapy for Cancer,” Nature 588 (2020): 693–698.

[109] L. Raccosta, R. Fontana, D. Maggioni, et al., “The Oxysterol-CXCR2 Axis Plays a Key Role in the Recruitment of Tumor-Promoting Neutrophils,” Journal of Experimental Medicine 210 (2013): 1711–1728.

[110] S. Zelenay, A. G. van der Veen, J. P. Böttcher, et al., “Cyclooxygenase-Dependent Tumor Growth Through Evasion of Immunity,” Cell 162 (2015): 1257–1270.

[111] F. Bayerl, P. Meiser, S. Donakonda, et al., “Tumor-Derived Prostaglandin E2 Programs cDC1 Dysfunction to Impair Intratumoral Orchestration of Anti-Cancer T Cell Responses,” Immunity 56 (2023): 1341–1358.e1311.

[112] J. P. Böttcher, E. Bonavita, P. Chakravarty, et al., “NK Cells Stimulate Recruitment of cDC1 Into the Tumor Microenvironment Promoting Cancer Immune Control,” Cell 172 (2018): 1022–1037.e1014.

[113] J. H. Chen, C. J. Perry, Y. C. Tsui, et al., “Prostaglandin E2 and Programmed Cell Death 1 Signaling Coordinately Impair CTL Function and Survival During Chronic Viral Infection,” Nature Medicine 21 (2015): 327–334.

[114] R. K. Sharma, Z. Chheda, V. R. Jala, and B. Haribabu, “Expression of Leukotriene B₄ Receptor-1 on CD8⁺ T Cells Is Required for Their Migration Into Tumors to Elicit Effective Antitumor Immunity,” Journal of Immunology 191 (2013): 3462–3470.

[115] P. Chakraborty, S. G. Vaena, K. Thyagarajan, et al., “Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-Tumor Activity,” Cell Reports 28 (2019): 1879–1893.e1877.

[116] P. Lau, G. Zhang, S. Zhao, et al., “Sphingosine Kinase 1 Promotes Tumor Immune Evasion by Regulating the MTA3-PD-L1 Axis,” Cellular & Molecular Immunology 19 (2022): 1153–1167.

[117] K. Kachler, M. Bailer, L. Heim, et al., “Enhanced Acid Sphingomyelinase Activity Drives Immune Evasion and Tumor Growth in Non-Small Cell Lung Carcinoma,” Cancer Research 77 (2017): 5963–5976.

[118] H. Yao, J. Lan, C. Li, et al., “Inhibiting PD-L1 Palmitoylation Enhances T-Cell Immune Responses Against Tumours,” Nature Biomedical Engineering 3 (2019): 306–317.

[119] M. Nakaya, Y. Xiao, X. Zhou, et al., “Inflammatory T Cell Responses Rely on Amino Acid Transporter ASCT2 Facilitation of Glutamine Uptake and mTORC1 Kinase Activation,” Immunity 40 (2014): 692–705.

[120] L. V. Sinclair, J. Rolf, E. Emslie, et al., “Control of Amino-Acid Transport by Antigen Receptors Coordinates the Metabolic Reprogramming Essential for T Cell Differentiation,” Nature Immunology 14 (2013): 500–508.

[121] R. D. Leone, L. Zhao, J. M. Englert, et al., “Glutamine Blockade Induces Divergent Metabolic Programs to Overcome Tumor Immune Evasion,” Science 366 (2019): 1013–1021.

[122] G. V. Long, R. Dummer, O. Hamid, et al., “Epacadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma (ECHO-301/KEYNOTE-252): A Phase 3, Randomised, Double-Blind Study,” The Lancet Oncology 20 (2019): 1083–1097.

[123] E. H. Ma, G. Bantug, T. Griss, et al., “Serine Is an Essential Metabolite for Effector T Cell Expansion,” Cell Metabolism 25 (2017): 345–357.

[124] C. Guo, Z. You, H. Shi, et al., “SLC38A2 and Glutamine Signalling in cDC1s Dictate Anti-Tumour Immunity,” Nature 620 (2023): 200–208.

[125] S. Cao, Y.-W. Hung, Y.-C. Wang, et al., “Glutamine Is Essential for Overcoming the Immunosuppressive Microenvironment in Malignant Salivary Gland Tumors,” Theranostics 12 (2022): 6038–6056.

[126] J. Ma, Y. Wu, L. Ma, et al., “A Blueprint for Tumor-Infiltrating B Cells Across Human Cancers,” Science 384 (2024): eadj4857.

[127] M.-H. Oh, I.-H. Sun, L. Zhao, et al., “Targeting Glutamine Metabolism Enhances Tumor-Specific Immunity by Modulating Suppressive Myeloid Cells,” The Journal of Clinical Investigation 130 (2020): 3865–3884.

[128] J. Huang, D. Liu, Y. Wang, et al., “Ginseng Polysaccharides Alter the Gut Microbiota and Kynurenine/Tryptophan Ratio, Potentiating the Antitumour Effect of Antiprogrammed Cell Death 1/Programmed Cell Death Ligand 1 (Anti-PD-1/PD-L1) Immunotherapy,” Gut 71 (2022): 734–745.

[129] A. Kumari, S. Syeda, K. Rawat, R. Kumari, and A. Shrivastava, “Melatonin Modulates L-Arginine Metabolism in Tumor-Associated Macrophages by Targeting Arginase 1 in Lymphoma,” Naunyn-Schmiedeberg's Archives of Pharmacology 397 (2024): 1163–1179.

[130] S. Meza-Perez, M. Liu, A. Silva-Sanchez, et al., “Proteobacteria Impair Anti-Tumor Immunity in the Omentum by Consuming Arginine,” Cell Host & Microbe 32 (2024): 1177–1191.e1177.

[131] Y. Bian, W. Li, D. M. Kremer, et al., “Cancer SLC43A2 Alters T Cell Methionine Metabolism and Histone Methylation,” Nature 585 (2020): 277–282.

[132] Y. Wu, J. Ma, X. Yang, et al., “Neutrophil Profiling Illuminates Anti-Tumor Antigen-Presenting Potency,” Cell 187 (2024): 1422–1439.e1424.

[133] Z. Wang, Z. Lu, S. Lin, et al., “Leucine-tRNA-Synthase-2-Expressing B Cells Contribute to Colorectal Cancer Immunoevasion,” Immunity 55 (2022): 1067–1081.e1068.

[134] Q. Zhou, Y. Peng, F. Ji, et al., “Targeting of SLC25A22 Boosts the Immunotherapeutic Response in KRAS-Mutant Colorectal Cancer,” Nature Communications 14 (2023): 4677.

[135] D.-H. Kim, Y. N. Kang, J. Jin, et al., “Glutamine-Derived Aspartate Is Required for eIF5A Hypusination-Mediated Translation of HIF-1α to Induce the Polarization of Tumor-Associated Macrophages,” Experimental & Molecular Medicine 56 (2024): 1123–1136.

[136] R. Ruiu, C. Cossu, A. Iacoviello, et al., “Cystine/Glutamate Antiporter xCT Deficiency Reduces Metastasis Without Impairing Immune System Function in Breast Cancer Mouse Models,” Journal of Experimental & Clinical Cancer Research: CR 42 (2023): 254.

[137] T. Xiong, P. He, M. Zhou, et al., “Glutamate Blunts Cell-Killing Effects of Neutrophils in Tumor Microenvironment,” Cancer Science 113 (2022): 1955–1967.

[138] Y. Ping, J. Shan, Y. Liu, et al., “Taurine Enhances the Antitumor Efficacy of PD-1 Antibody by Boosting CD8+ T Cell Function,” Cancer Immunology, Immunotherapy: CII 72 (2023): 1015–1027.

[139] T. Cao, W. Zhang, Q. Wang, et al., “Cancer SLC6A6-Mediated Taurine Uptake Transactivates Immune Checkpoint Genes and Induces Exhaustion in CD8+ T Cells,” Cell 187 (2024): 2288–2304.e2227.

[140] Z. Zheng, J. Wei, X. Hou, et al., “A High Hepatic Uptake of Conjugated Bile Acids Promotes Colorectal Cancer-Associated Liver Metastasis,” Cells 11 (2022): 3810.

[141] S. Saha, M. Ghosh, J. Li, et al., “Serine Depletion Promotes Antitumor Immunity by Activating Mitochondrial DNA-Mediated cGAS-STING Signaling,” Cancer Research 84 (2024): 2645–2659.

[142] H. Yuan, X. Wu, Q. Wu, et al., “Lysine Catabolism Reprograms Tumour Immunity Through Histone Crotonylation,” Nature 617 (2023): 818–826.

[143] M. H. Oh, I. H. Sun, L. Zhao, et al., “Targeting Glutamine Metabolism Enhances Tumor-Specific Immunity by Modulating Suppressive Myeloid Cells,” Journal of Clinical Investigation 130 (2020): 3865–3884.

[144] J. K. Byun, M. Park, S. Lee, et al., “Inhibition of Glutamine Utilization Synergizes With Immune Checkpoint Inhibitor to Promote Antitumor Immunity,” Molecular Cell 80 (2020): 592–606.e598.

[145] M. Praharaj, F. Shen, A. J. Lee, et al., “Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers,” Cancer Immunology Research 12 (2024): 854–875.

[146] R. Geiger, J. C. Rieckmann, T. Wolf, et al., “L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-Tumor Activity,” Cell 167 (2016): 829–842.e813.

[147] P. C. Rodriguez, D. G. Quiceno, J. Zabaleta, et al., “Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses,” Cancer Research 64 (2004): 5839–5849.

[148] M. Czystowska-Kuzmicz, A. Sosnowska, D. Nowis, et al., “Small Extracellular Vesicles Containing Arginase-1 Suppress T-Cell Responses and Promote Tumor Growth in Ovarian Carcinoma,” Nature Communications 10 (2019): 3000.

[149] P. C. Rodriguez, A. H. Zea, J. DeSalvo, et al., “L-Arginine Consumption by Macrophages Modulates the Expression of CD3 Zeta Chain in T Lymphocytes,” Journal of Immunology 171 (2003): 1232–1239.

[150] C. S. Hayes, A. C. Shicora, M. P. Keough, et al., “Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment,” Cancer Immunology Research 2 (2014): 274–285.

[151] E. T. Alexander, K. Mariner, J. Donnelly, O. T. Phanstiel, and S. K. Gilmour, “Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade,” Molecular Cancer Therapeutics 19 (2020): 2012–2022.

[152] G. Bündgen, A. Ulges, J. Pietruschka, et al., “Polyamines Regulate Adaptive Antitumor Immunity by Functional Specialization of Regulatory T Cells,” Immunity 58 (2025): 2019–2034.e2011.

[153] D. H. Munn, M. Zhou, J. T. Attwood, et al., “Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism,” Science 281 (1998): 1191–1193.

[154] J. D. Mezrich, J. H. Fechner, X. Zhang, et al., “An Interaction Between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells,” Journal of Immunology 185 (2010): 3190–3198.

[155] Y. Liu, X. Liang, W. Dong, et al., “Tumor-Repopulating Cells Induce PD-1 Expression in CD8⁺ T Cells by Transferring Kynurenine and AhR Activation,” Cancer Cell 33 (2018): 480–494.e487.

[156] M. Pandit, Y. S. Kil, J. H. Ahn, et al., “Methionine Consumption by Cancer Cells Drives a Progressive Upregulation of PD-1 Expression in CD4 T Cells,” Nature Communications 14 (2023): 2593.

[157] P. Sharma, A. Guo, S. Poudel, et al., “Early Methionine Availability Attenuates T Cell Exhaustion,” Nature Immunology 26 (2025): 1384–1396.

[158] H. Tong, Z. Jiang, L. Song, et al., “Dual Impacts of Serine/Glycine-Free Diet in Enhancing Antitumor Immunity and Promoting Evasion via PD-L1 Lactylation,” Cell Metabolism 36 (2024): 2493–2510.e2499.

[159] E. N. Arner and J. C. Rathmell, “Metabolic Programming and Immune Suppression in the Tumor Microenvironment,” Cancer Cell 41 (2023): 421–433.

[160] H. Wang, F. Franco, Y. C. Tsui, et al., “CD36-Mediated Metabolic Adaptation Supports Regulatory T Cell Survival and Function in Tumors,” Nature Immunology 21 (2020): 298–308.

[161] C. Liu, M. Chikina, R. Deshpande, et al., “Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8⁺ T Cell-Derived Interferon-γ,” Immunity 51 (2019): 381–397.e386.

[162] P. Yang, H. Qin, Y. Li, et al., “CD36-Mediated Metabolic Crosstalk Between Tumor Cells and Macrophages Affects Liver Metastasis,” Nature Communications 13 (2022): 5782.

[163] Y. Kidani, H. Elsaesser, M. B. Hock, et al., “Sterol Regulatory Element-Binding Proteins Are Essential for the Metabolic Programming of Effector T Cells and Adaptive Immunity,” Nature Immunology 14 (2013): 489–499.

[164] J. Baardman, S. G. S. Verberk, S. van der Velden, et al., “Macrophage ATP Citrate Lyase Deficiency Stabilizes Atherosclerotic Plaques,” Nature Communications 11 (2020): 6296.

[165] Y. Chen, Y. Dai, X. Wang, and J. Liu, “Exploring the Role of Protein Palmitoylation in Cancer Progression and Therapy: A Comprehensive Bibliometric Study (2004–2024),” Discover Oncology 16 (2025): 1221.

[166] R. Wang, A. Zhuang, Y. Wu, et al., “S-Palmitoylation: A Novel Player in Cancer and Its Emerging Therapeutic Implications,” Cell Investigation 1 (2025): 100032.

[167] M. Song, T. A. Sandoval, C.-S. Chae, et al., “IRE1α–XBP1 Controls T Cell Function in Ovarian Cancer by Regulating Mitochondrial Activity,” Nature 562 (2018): 423–428.

[168] S. B. Lacher, J. Dörr, G. P. de Almeida, et al., “PGE2 Limits Effector Expansion of Tumour-Infiltrating Stem-Like CD8+ T Cells,” Nature 629 (2024): 417–425.

[169] M. Morotti, A. J. Grimm, H. C. Hope, et al., “PGE2 Inhibits TIL Expansion by Disrupting IL-2 Signalling and Mitochondrial Function,” Nature 629 (2024): 426–434.

[170] D. Holt, X. Ma, N. Kundu, and A. Fulton, “Prostaglandin E₂ (PGE₂) Suppresses Natural Killer Cell Function Primarily Through the PGE₂ Receptor EP4,” Cancer Immunology, Immunotherapy 60 (2011): 1577–1586.

[171] G. Gao, W. Liao, P. Shu, et al., “Targeting Sphingosine 1-Phosphate Receptor 3 Inhibits T-Cell Exhaustion and Regulates Recruitment of Proinflammatory Macrophages to Improve Antitumor Efficacy of CAR-T Cells Against Solid Tumor,” Journal for ImmunoTherapy of Cancer 11 (2023): e006343.

[172] Q. Zhou, Y. Meng, D. Li, et al., “Ferroptosis in Cancer: From Molecular Mechanisms to Therapeutic Strategies,” Signal Transduction and Targeted Therapy 9 (2024): 55.

[173] P. Liao, W. Wang, W. Wang, et al., “CD8⁺T Cells and Fatty Acids Orchestrate Tumor Ferroptosis and Immunity via ACSL4,” Cancer Cell 40 (2022): 365–378.e366.

[174] S. Sheppard, K. Srpan, W. Lin, et al., “Fatty Acid Oxidation Fuels Natural Killer Cell Responses Against Infection and Cancer,” PNAS 121 (2024): e2319254121.

[175] R. B. Delconte, M. Owyong, E. K. Santosa, et al., “Fasting Reshapes Tissue-Specific Niches to Improve NK Cell-Mediated Anti-Tumor Immunity,” Immunity 57 (2024): 1923–1938.e1927.

[176] D. Jiao, R. Sun, X. Ren, et al., “Lipid Accumulation-Mediated Histone Hypoacetylation Drives Persistent NK Cell Dysfunction in Anti-Tumor Immunity,” Cell Reports 42 (2023): 113211.

[177] C. H. Chang, J. Qiu, D. O'Sullivan, et al., “Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression,” Cell 162 (2015): 1229–1241.

[178] P. C. Ho, J. D. Bihuniak, A. N. Macintyre, et al., “Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-Tumor T Cell Responses,” Cell 162 (2015): 1217–1228.

[179] J. A. Shyer, R. A. Flavell, and W. Bailis, “Metabolic Signaling in T Cells,” Cell Research 30 (2020): 649–659.

[180] M. O. Johnson, M. M. Wolf, M. Z. Madden, et al., “Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism,” Cell 175 (2018): 1780–1795.e1719.

[181] G. P. Lobel, N. Han, W. A. Molina Arocho, et al., “Glutamine Is Critical for the Maintenance of Type 1 Conventional Dendritic Cells in Normal Tissue and the Tumor Microenvironment,” PNAS 121 (2024): e2412157121.

[182] R. Pillai, S. E. LeBoeuf, Y. Hao, et al., “Glutamine Antagonist DRP-104 Suppresses Tumor Growth and Enhances Response to Checkpoint Blockade in KEAP1 Mutant Lung Cancer,” Science Advances 10 (2024): eadm9859.

[183] Y. Chang, N. Wang, S. Li, et al., “SLC3A2-Mediated Lysine Uptake by Cancer Cells Restricts T-Cell Activity in Hepatocellular Carcinoma,” Cancer Research 85 (2025): 2250–2267.

[184] R. E. Menjivar, Z. C. Nwosu, W. Du, et al., “Arginase 1 Is a Key Driver of Immune Suppression in Pancreatic Cancer,” Elife 12 (2023): e80721.

[185] S. Canè, R. M. Barouni, M. Fabbi, et al., “Neutralization of NET-Associated Human ARG1 Enhances Cancer Immunotherapy,” Science Translational Medicine 15 (2023): eabq6221.

[186] M. L. Broz, M. Binnewies, B. Boldajipour, et al., “Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity,” Cancer Cell 26 (2014): 638–652.

[187] I. Kaymak, M. J. Watson, B. M. Oswald, et al., “ACLY and ACSS2 Link Nutrient-Dependent Chromatin Accessibility to CD8 T Cell Effector Responses,” Journal of Experimental Medicine 221 (2024): e20231820.

[188] S. Ma, M. S. Dahabieh, T. H. Mann, et al., “Nutrient-Driven Histone Code Determines Exhausted CD8⁺ T Cell Fates,” Science 387 (2025): eadj3020.

[189] Z. Wu, Y. Zhang, Y. Cheng, et al., “PD-1 Blockade Plus COX Inhibitors in dMMR Metastatic Colorectal Cancer: Clinical, Genomic, and Immunologic Analyses From the PCOX Trial,” Med 5 (2024): 998–1015.e1016.

[190] A. Naing, K. P. Papadopoulos, M. J. Pishvaian, et al., “First-in-Human Phase 1 Study of the Arginase Inhibitor INCB001158 Alone or Combined With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumours,” BMJ Oncology 3 (2024): e000249.

[191] M. A. Gouda, M. H. Voss, H. Tawbi, et al., “A Phase I/II Study of the Safety and Efficacy of Telaglenastat (CB-839) in Combination With nivolumab in Patients With Metastatic Melanoma, Renal Cell Carcinoma, and Non-Small-Cell Lung Cancer,” ESMO Open 10 (2025): 104536.

[192] Y. Yokoyama, T. M. Estok, and R. Wild, “Sirpiglenastat (DRP-104) Induces Antitumor Efficacy Through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems,” Molecular Cancer Therapeutics 21 (2022): 1561–1572.

[193] A. Naing, J. P. Eder, S. A. Piha-Paul, et al., “Preclinical Investigations and a First-in-Human Phase I Trial of M4112, the First Dual Inhibitor of Indoleamine 2,3-Dioxygenase 1 and Tryptophan 2,3-Dioxygenase 2, in Patients With Advanced Solid Tumors,” Journal for ImmunoTherapy of Cancer 8 (2020): e000870.

[194] D. H. Aggen, M. McKean, J. H. Hoffman-Censits, et al., “IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and With Nivolumab in Patients With Advanced Solid Tumors and Urothelial Carcinoma,” Clinical Cancer Research 32 (2026): 94–105.

[195] M. D. Mattes, I. Koturbash, C. N. Leung, S. Wen, and G. M. Jacobson, “A Phase I Trial of a Methionine Restricted Diet With Concurrent Radiation Therapy,” Nutrition and Cancer 76 (2024): 463–468.

[196] H. C. Chang, C. Y. Tsai, C. L. Hsu, et al., “Asparagine Deprivation Enhances T Cell Antitumour Response in Patients via ROS-Mediated Metabolic and Signal Adaptations,” Nature Metabolism 7 (2025): 918–927.

[197] K. Hu, K. Li, J. Lv, et al., “Suppression of the SLC7A11/Glutathione Axis Causes Synthetic Lethality in KRAS-Mutant Lung Adenocarcinoma,” Journal of Clinical Investigation 130 (2020): 1752–1766.

[198] D. S. Hong, A. Parikh, G. I. Shapiro, et al., “First-in-Human Phase I Study of Immunomodulatory E7046, an Antagonist of PGE₂-Receptor E-Type 4 (EP4), in Patients With Advanced Cancers,” Journal for ImmunoTherapy of Cancer 8 (2020): e000222.

[199] L. Wyrwicz, M. Saunders, M. Hall, et al., “AN0025, a Novel Antagonist of PGE2-Receptor E-Type 4 (EP4), in Combination With Total Neoadjuvant Treatment of Advanced Rectal Cancer,” Radiotherapy and Oncology 185 (2023): 109669.

[200] A. Kawazoe, K. Yamaguchi, T. Hamaguchi, et al., “ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer,” Cancer Science 116 (2025): 2523–2536.

[201] L. K. Boroughs and R. J. DeBerardinis, “Metabolic Pathways Promoting Cancer Cell Survival and Growth,” Nature Cell Biology 17 (2015): 351–359.

[202] A. Boudreau, H. E. Purkey, A. Hitz, et al., “Metabolic Plasticity Underpins Innate and Acquired Resistance to LDHA Inhibition,” Nature Chemical Biology 12 (2016): 779–786.

[203] Z. E. Stine, Z. T. Schug, J. M. Salvino, and C. V. Dang, “Targeting Cancer Metabolism in the Era of Precision Oncology,” Nature Reviews Drug Discovery 21 (2022): 141–162.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.